Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab with carboplatin and paclitaxel in advanced melanoma
NCT01676649Phase 2Active, not recruiting
- Sponsor
- Jewish General Hospital
- Start
- Nov 2012
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by Jewish General Hospital. Started Nov 2012; status: active, not recruiting.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01676649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676649.